RARE DISEASE
Fetal and neonatal alloimmune thrombocytopenia
Fetal and neonatal alloimmune thrombocytopenia
Fetal and neonatal alloimmune thrombocytopenia
Synonyms: FNAIT, NAIT
Synonyms: FNAIT, NAIT
Synonyms: FNAIT, NAIT
Drug discovery
7
drugs
With orphan designations
Overview
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare immune-mediated condition where maternal IgG antibodies target fetal platelet antigens inherited from the father, causing severe thrombocytopenia. It is the leading cause of intracranial hemorrhage (ICH) in term neonates, with up to 20% of cases involving antenatal bleeding. Unlike Rh disease, FNAIT often occurs in first pregnancies [1][2][4][15].
Therapies
Antenatal: Maternal IV immunoglobulin (IVIG) ± corticosteroids, stratified by risk [3][8][11].
Postnatal: Immediate HPA-matched platelet transfusion; unmatched platelets as temporary therapy [3][11][17].
Invasive interventions (e.g., intrauterine platelet transfusions) limited due to high complication risk [6][11].
Categories: rare hematological diseases
Research Papers
348 drug discovery papers about Fetal and neonatal alloimmune thrombocytopenia, with 1 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
348 drug discovery papers about Fetal and neonatal alloimmune thrombocytopenia, with 1 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-14 | Fusion of IgG antibodies to albumin inhibits transport across the placenta.
Immunoglobulin G (IgG)-based monoclonal antibodies are effective therapies for cancer, autoimmune diseases, and migraine. However, they are actively transported across the placenta by the neonatal Fc receptor (FcRn), limiting their use during pregnancy. Using mouse models and an ex vivo human placental perfusion system, we show that although FcRn binds albumin independently of IgG, albumin is not transported to the fetus in mice or across human placental tissue. Fusion of IgG to albumin markedly reduced transplacental transport in both models while preserving the prolonged plasma half-life conferred by FcRn. Similarly, fragment antigen-binding fragments fused to engineered albumin with enhanced FcRn binding showed minimal fetal exposure. In a mouse model of fetal and neonatal alloimmune thrombocytopenia, albumin fusion of an anti-human platelet antigen IgG reduced fetal antibody transfer and attenuated thrombocytopenia in the offspring. These findings identify albumin as an attractive fusion partner for biologics intended to minimize fetal exposure during pregnancy.
2026-06-11 | Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs when maternal anti-fetal platelet antibodies, most frequently against HPA-1a, cause fetal platelet destruction. The precise pathogenic mechanisms remain incompletely understood. Here, we examined potential mechanisms underlying anti-HPA-1a-mediated platelet clearance, focusing on phagocytosis, complement fixation, platelet activation, and desialylation. Anti-HPA-1a antibodies in pooled plasma and in 9 of 10 individual FNAIT patient samples induced FcγR-dependent platelet phagocytosis in vitro, indicating this as the major contributor to platelet destruction. In contrast, complement fixation, platelet activation (CD62P expression), and desialylation (RCA-I binding) were observed in only a minority of patients. To model anti-HPA-1a-mediated platelet clearance in vivo, we developed a dual-humanized mouse model combining HPA-1a-expressing platelets (from APLDQ transgenic mice) with mice engineered to express human FcγRs in place of murine FcγRs. Platelets from APLDQ mice sensitized with anti-HPA-1a sera underwent rapid clearance in these FcγR-humanized recipients. Pre-treatment with an FcγRIII-blocking monovalent antibody significantly reduced clearance, confirming FcγRIII's central role in mediating platelet destruction. These results demonstrate that FcγRIII-dependent phagocytosis is a dominant mechanism in anti-HPA-1a-driven platelet clearance in this model. Although complement activation and platelet desialylation were observed in a minority of samples, their contribution to platelet destruction remains speculative. Together, these findings highlight the complexity of FNAIT pathophysiology yet identify FcγRIII blockade as a promising strategy to prevent platelet clearance in this disease.
2026-04-17 | New perspectives on fetal and neonatal alloimmune thrombocytopenia for obstetricians.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a serious disorder that arises when a mother produces alloantibodies against specific human platelet antigens (HPAs) expressed on fetal platelets. These maternal alloantibodies cross the placenta and destroy fetal platelets, significantly increasing the risk of fetal or neonatal intracranial hemorrhage (ICH). Indeed, FNAIT is the leading cause of isolated severe thrombocytopenia in otherwise healthy neonates. In this review, we summarize recent advances to provide obstetricians and maternal-fetal medicine specialists with an updated overview of FNAIT, encompassing its pathophysiology, clinical features, diagnostic strategies, antenatal management, delivery planning, and postnatal care. Although the prophylactic interventions remain at an early stage, HPA histo-incompatibility prescreening is already available at a suitable cost, and the development of NAITgam, a targeted immunoglobulin preparation, represents a promising advance. While the widespread implementation of screening and prophylaxis may take years, such measures have the potential to significantly reduce the incidence and severity of FNAIT. Currently, the antenatal administration of intravenous immunoglobulin (IVIg), with or without corticosteroids, remains the safest and most effective treatment for high-risk pregnancies. Looking ahead, animal model data continue to provide valuable insights that may inform the development of novel preventive and therapeutic strategies. Ultimately, the implementation of a national screening program could prevent severe complications and help mitigate the long-term societal and healthcare burden of FNAIT.
2026-04-14 | Maternal anti-HPA-1a antibodies block αIIbβ3 and αvβ3 integrin activation which correlates with FNAIT disease severity.
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) is a disorder caused by a mismatch in human platelet antigens (HPAs), leading to maternal antibody formation and platelet destruction in the fetus or neonate. The clinically most relevant antigen is HPA-1a on the b3 subunit of integrins aIIbb3 and avb3, which are conformationally regulated cell adhesion receptors on platelets and endothelial cells, crucial for hemostasis and vascular integrity. The clinical effects of anti-HPA-1a alloimmunization are highly heterogeneous and range from no symptoms to intracranial hemorrhage, potentially causing perinatal death or lifelong complications. However, determinants of disease severity are largely unknown, which hampers implementation of screening programs to identify alloimmunized high-risk women who will benefit from treatment. Using recombinant anti-HPA-1a antibodies and a cohort of retrospective FNAIT samples associated with mild or severe disease, we report here that the tested anti-HPA-1a antibodies inhibit binding of integrins avb3/aIIbb3 to ligands (vitronectin, fibronectin, and fibrinogen) and cell adhesion. Inhibition is dependent on antibody concentration, is mediated by the antibody Fab and does not require the Fc-tail, and is abolished when integrins are forced into a constitutively extended conformation. Furthermore, the extent of integrin inhibition correlates with disease severity. Together, our data demonstrate that anti-HPA-1a antibodies can block integrin activation, which likely contributes strongly to disease severity in FNAIT. These results aid development of a prenatal diagnostic test to identify pregnancies at high risk of developing FNAIT and associated severe complications. In addition, these data reveal novel opportunities for allosteric inhibition of b3 integrin activation.
2026-03-09 | High-resolution cryo-EM structure of integrin αIIbβ3 bound to disease-causing maternal HPA-1a antibody that blocks integrin activation
Abstract Integrins promote immunity, embryonic development, wound healing, and hemostasis, and are activated by ‘bent/closed’ to ‘extended/open’ conformational changes. Integrin αIIbβ3, being crucial for platelet activation and aggregation, is a therapeutic target for bleeding disorders and thrombosis. Human Platelet Antigen-1a (HPA-1a) on β3 is recognized by pregnancy-associated maternal alloantibodies, potentially causing fetal/neonatal alloimmune thrombocytopenia (FNAIT) and even intracranial hemorrhage or perinatal death. However, severe disease determinants are largely unknown. We report the first structure of an anti-HPA-1a antibody fragment (Fab 26.4) in complex with integrin αIIbβ3 at high resolution by cryo-electron microscopy. Fab 26.4 binding traps αIIbβ3 in the inactive, bent/closed conformation, is incompatible with integrin extension, and inhibits αIIbβ3-dependent fibrinogen binding and platelet aggregation. Thus, anti-HPA-1a antibodies directly impair integrin activation by preventing required conformational changes. These insights will improve FNAIT diagnostics and treatment, and spark the development of novel allosteric inhibitors against β3 integrins for future therapeutic applications.
2026-08-14 | Fusion of IgG antibodies to albumin inhibits transport across the placenta.
Immunoglobulin G (IgG)-based monoclonal antibodies are effective therapies for cancer, autoimmune diseases, and migraine. However, they are actively transported across the placenta by the neonatal Fc receptor (FcRn), limiting their use during pregnancy. Using mouse models and an ex vivo human placental perfusion system, we show that although FcRn binds albumin independently of IgG, albumin is not transported to the fetus in mice or across human placental tissue. Fusion of IgG to albumin markedly reduced transplacental transport in both models while preserving the prolonged plasma half-life conferred by FcRn. Similarly, fragment antigen-binding fragments fused to engineered albumin with enhanced FcRn binding showed minimal fetal exposure. In a mouse model of fetal and neonatal alloimmune thrombocytopenia, albumin fusion of an anti-human platelet antigen IgG reduced fetal antibody transfer and attenuated thrombocytopenia in the offspring. These findings identify albumin as an attractive fusion partner for biologics intended to minimize fetal exposure during pregnancy.
2026-06-11 | Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) occurs when maternal anti-fetal platelet antibodies, most frequently against HPA-1a, cause fetal platelet destruction. The precise pathogenic mechanisms remain incompletely understood. Here, we examined potential mechanisms underlying anti-HPA-1a-mediated platelet clearance, focusing on phagocytosis, complement fixation, platelet activation, and desialylation. Anti-HPA-1a antibodies in pooled plasma and in 9 of 10 individual FNAIT patient samples induced FcγR-dependent platelet phagocytosis in vitro, indicating this as the major contributor to platelet destruction. In contrast, complement fixation, platelet activation (CD62P expression), and desialylation (RCA-I binding) were observed in only a minority of patients. To model anti-HPA-1a-mediated platelet clearance in vivo, we developed a dual-humanized mouse model combining HPA-1a-expressing platelets (from APLDQ transgenic mice) with mice engineered to express human FcγRs in place of murine FcγRs. Platelets from APLDQ mice sensitized with anti-HPA-1a sera underwent rapid clearance in these FcγR-humanized recipients. Pre-treatment with an FcγRIII-blocking monovalent antibody significantly reduced clearance, confirming FcγRIII's central role in mediating platelet destruction. These results demonstrate that FcγRIII-dependent phagocytosis is a dominant mechanism in anti-HPA-1a-driven platelet clearance in this model. Although complement activation and platelet desialylation were observed in a minority of samples, their contribution to platelet destruction remains speculative. Together, these findings highlight the complexity of FNAIT pathophysiology yet identify FcγRIII blockade as a promising strategy to prevent platelet clearance in this disease.
2026-04-17 | New perspectives on fetal and neonatal alloimmune thrombocytopenia for obstetricians.
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a serious disorder that arises when a mother produces alloantibodies against specific human platelet antigens (HPAs) expressed on fetal platelets. These maternal alloantibodies cross the placenta and destroy fetal platelets, significantly increasing the risk of fetal or neonatal intracranial hemorrhage (ICH). Indeed, FNAIT is the leading cause of isolated severe thrombocytopenia in otherwise healthy neonates. In this review, we summarize recent advances to provide obstetricians and maternal-fetal medicine specialists with an updated overview of FNAIT, encompassing its pathophysiology, clinical features, diagnostic strategies, antenatal management, delivery planning, and postnatal care. Although the prophylactic interventions remain at an early stage, HPA histo-incompatibility prescreening is already available at a suitable cost, and the development of NAITgam, a targeted immunoglobulin preparation, represents a promising advance. While the widespread implementation of screening and prophylaxis may take years, such measures have the potential to significantly reduce the incidence and severity of FNAIT. Currently, the antenatal administration of intravenous immunoglobulin (IVIg), with or without corticosteroids, remains the safest and most effective treatment for high-risk pregnancies. Looking ahead, animal model data continue to provide valuable insights that may inform the development of novel preventive and therapeutic strategies. Ultimately, the implementation of a national screening program could prevent severe complications and help mitigate the long-term societal and healthcare burden of FNAIT.
2026-04-14 | Maternal anti-HPA-1a antibodies block αIIbβ3 and αvβ3 integrin activation which correlates with FNAIT disease severity.
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) is a disorder caused by a mismatch in human platelet antigens (HPAs), leading to maternal antibody formation and platelet destruction in the fetus or neonate. The clinically most relevant antigen is HPA-1a on the b3 subunit of integrins aIIbb3 and avb3, which are conformationally regulated cell adhesion receptors on platelets and endothelial cells, crucial for hemostasis and vascular integrity. The clinical effects of anti-HPA-1a alloimmunization are highly heterogeneous and range from no symptoms to intracranial hemorrhage, potentially causing perinatal death or lifelong complications. However, determinants of disease severity are largely unknown, which hampers implementation of screening programs to identify alloimmunized high-risk women who will benefit from treatment. Using recombinant anti-HPA-1a antibodies and a cohort of retrospective FNAIT samples associated with mild or severe disease, we report here that the tested anti-HPA-1a antibodies inhibit binding of integrins avb3/aIIbb3 to ligands (vitronectin, fibronectin, and fibrinogen) and cell adhesion. Inhibition is dependent on antibody concentration, is mediated by the antibody Fab and does not require the Fc-tail, and is abolished when integrins are forced into a constitutively extended conformation. Furthermore, the extent of integrin inhibition correlates with disease severity. Together, our data demonstrate that anti-HPA-1a antibodies can block integrin activation, which likely contributes strongly to disease severity in FNAIT. These results aid development of a prenatal diagnostic test to identify pregnancies at high risk of developing FNAIT and associated severe complications. In addition, these data reveal novel opportunities for allosteric inhibition of b3 integrin activation.
2026-03-09 | High-resolution cryo-EM structure of integrin αIIbβ3 bound to disease-causing maternal HPA-1a antibody that blocks integrin activation
Abstract Integrins promote immunity, embryonic development, wound healing, and hemostasis, and are activated by ‘bent/closed’ to ‘extended/open’ conformational changes. Integrin αIIbβ3, being crucial for platelet activation and aggregation, is a therapeutic target for bleeding disorders and thrombosis. Human Platelet Antigen-1a (HPA-1a) on β3 is recognized by pregnancy-associated maternal alloantibodies, potentially causing fetal/neonatal alloimmune thrombocytopenia (FNAIT) and even intracranial hemorrhage or perinatal death. However, severe disease determinants are largely unknown. We report the first structure of an anti-HPA-1a antibody fragment (Fab 26.4) in complex with integrin αIIbβ3 at high resolution by cryo-electron microscopy. Fab 26.4 binding traps αIIbβ3 in the inactive, bent/closed conformation, is incompatible with integrin extension, and inhibits αIIbβ3-dependent fibrinogen binding and platelet aggregation. Thus, anti-HPA-1a antibodies directly impair integrin activation by preventing required conformational changes. These insights will improve FNAIT diagnostics and treatment, and spark the development of novel allosteric inhibitors against β3 integrins for future therapeutic applications.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
7 orphan drug designations for Fetal and neonatal alloimmune thrombocytopenia.
7 orphan drug designations for Fetal and neonatal alloimmune thrombocytopenia.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Nipocalimab | antibodies | EMA | 2025-04-16 | — | Janssen Cilag International N.V. |
nipocalimab | antibodies | FDA | 2023-12-14 | — | Janssen Research & Development, LLC |
recombinant human IgG monoclonal HPA-1a antibody | antibodies | FDA | 2020-07-01 | — | Rallybio IPA, LLC |
Anti-(integrin beta-3) human monoclonal antibody | antibodies | EMA | 2020-04-22 | — | FGK Representative Service GmbH |
human platelet antigen-1a immunoglobulin (anti-HPA-1a) | antibodies | FDA | 2013-06-27 | — | Rallybio IPA, LLC |
Human platelet antigen 1a immunoglobulin | antibodies | EMA | 2011-10-27 | — | FGK Representative Service GmbH |
Eptacog alfa (activated) | — | EMA | 2007-03-20 | — | Novo Nordisk A/S |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.